Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$170.59 USD

170.59
8,956,942

-0.15 (-0.09%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $170.91 +0.32 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

A Look at Pharma ETFs After Strong Q1 Earnings

by Sweta Killa

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

Zacks Equity Research

TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up

by Zacks Equity Research

TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.

Zacks Equity Research

HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.

Zacks Equity Research

The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie

by Zacks Equity Research

Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.

Zacks Equity Research

Should WisdomTree U.S. Total Dividend ETF (DTD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DTD

Zacks Equity Research

The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific

by Zacks Equity Research

GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.

Zacks Equity Research

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?

by Kinjel Shah

Both JNJ and ABBV expect their sales and profits to improve in 2025.

Zacks Equity Research

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VALQ

Urmimala Biswas headshot

MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know

by Urmimala Biswas

Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.

Zacks Equity Research

AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth

by Zacks Equity Research

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

Zacks Equity Research

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

by Zacks Equity Research

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.

Zacks Equity Research

Is WisdomTree U.S. Total Dividend ETF (DTD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DTD

Zacks Equity Research

The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

by Zacks Equity Research

Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).

Zacks Equity Research

GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance

by Zacks Equity Research

GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.

Shaun Pruitt headshot

Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?

by Shaun Pruitt

Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.

Zacks Equity Research

Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales

by Zacks Equity Research

PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.

Zacks Equity Research

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Zacks Equity Research

GSK to Report First-Quarter Earnings: Is a Beat in Store?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View

by Zacks Equity Research

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.

Zacks Equity Research

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS